GSK cuts losses on Synta elesclomol deal
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has called time on its $1 billion elesclomol deal with Synta Pharmaceuticals after a late-stage trial for the anticancer in metastatic melanoma missed its primary endpoint. To date, GSK had invested approximately $130 million during the nearly two-year span of its agreement with the US firm.